ClinicalTrials.gg
Sign In

Pathologic Complete Response clinical trials

The registry lists 138 studies for Pathologic Complete Response across more than 10 countries. 57 are recruiting or about to start. 20 of them are mainly about Pathologic Complete Response (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Pathologic Complete Response studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting
43
Completed
42
Status unknown
19
Not yet recruiting
14
Active, not recruiting
9
Withdrawn
6

Phase

Phase 2
48
Phase 3
18
Phase 1
10
Phase 4
5
Early Phase 1
1

Where

China
47
United States
28
France
17
Germany
11
Netherlands
10
Italy
9

Who runs them

Sixth Affiliated Hospital, Sun Yat-sen University (6) · Henan Cancer Hospital (4) · Tang-Du Hospital (3) · Assistance Publique - Hôpitaux de Paris (3) · The Netherlands Cancer Institute (3) · Fudan University (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Centre Leon Berard (2)

What is being tested here

Drugs under test in Pathologic Complete Response studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Trastuzumab305
Paclitaxel216
Toripalimab203
Trastuzumab rezetecan202
Tretinoin202
Pembrolizumab103
Cyclophosphamide133
Olaparib112
Oxaliplatin112
Albumin-Bound Paclitaxel102

Drug classes tested here Immune checkpoint inhibitors 7 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antimitotic agents 2 open · Alkylating agents 1 open · PARP inhibitors 1 open

Coming up

8phase 3 studies under way
15studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 43 Pathologic Complete Response studies recruiting now, 22 (51%) set no upper age limit and 15 (35%) stop at 75 or younger. 4 (9%) take children under 18. 10 (23%) are for women only and 1 (2%) for men only; 1 (2%) take healthy volunteers.

Recruiting studies that take each age, of 43
AgeWomenMen
101 (2%)1 (2%)
1838 (88%)31 (72%)
3040 (93%)32 (74%)
4041 (95%)32 (74%)
5041 (95%)32 (74%)
6541 (95%)32 (74%)
7534 (79%)28 (65%)
8521 (49%)17 (40%)

Across all 138 studies, recruiting or not: 30% stop at 75 or younger and 8% at 65; 9% take children; 28% are for women only and 1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 11, 2026.

Started recruiting1

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 138. Browse all 138 → or search them.